Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRAS^G12R-mutant pancreatic ductal adenocarcinoma.

ABSTRACT: Background Preclinical evidence has suggested that a subset of pancreatic cancers with the G12R mutational isoform of the KRAS oncogene is more sensitive to MAPK pathway blockade than pancreatic tumors with other KRAS isoforms. We conducted a biomarker-driven trial of selumetinib (KOSELUGO™; ARRY-142886), an orally active, allosteric mitogen-activated protein kinase 1 and 2 (MEK1/2) inhibitor, in pancreas cancer patients with somatic KRAS^G12R mutations. Methods In this two-stage, phase II study (NCT03040986) patients with advanced pancreas cancer harboring somatic KRAS^G12R variants who had received at least one standard-of-care systemic therapy regimen received 75 mg selumetinib orally twice a day until disease progression or unacceptable toxicity occurred. The primar

SUBMITTER: Kenney C 

PROVIDER: S-EPMC8068685 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature